Literature DB >> 1103141

Leukocyte migration inhibitory factor (LMIF) induced by concanavalin A: standardized microassay for production in vitro.

A J Górski, B Dupont, J A Hansen, R A Good.   

Abstract

A standardized microculture system has been developed to assess the ability of lymphocytes to secrete leukocyte migration inhibitory factor (LMIF) in response to the nonspecific mitogen concanavalin(Con A). LMIF-rich supernates collected from stimulated lymphocytes cultured in plastic microtiter plates are assayed by pulse exposure of purified human granulocytes and inhibition of their migration in agarose medium. LMIF activity in this system is suppressed by the protein synthesis inhibitor puromycin, but not by inhibition of lymphocyte proliferation by irradiation. It is demonstrated that normal lymphocytes stimulated with mitogen elaborate LMIF activity, while lymphocytes from malignant lymphoma patients are frequently unable to produce it. Thus, mitogen-induced mediator production may be a useful parameter in further characterization of primary and secondary immunodeficiencies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103141      PMCID: PMC432949          DOI: 10.1073/pnas.72.8.3197

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Serum migration inhibitory activity in patients with posttransplantation hepatic dysfunction.

Authors:  M Torisu; T Yoshida; S Cohen
Journal:  Clin Immunol Immunopathol       Date:  1975-01

2.  Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.

Authors:  T Yoshida; R Edelson; S Cohen; I Green
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

3.  A modified agarose method for detection of migration inhibitory factor and delineation of its antigen dependency.

Authors:  R H Weisbart; J E Cunningham; R Bluestone; L S Goldberg
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

4.  Murine spleen leukocytes as an inhibitable target cell system for human MIF.

Authors:  A J Górski
Journal:  Cell Immunol       Date:  1974-05       Impact factor: 4.868

5.  Migration inhibition factor and blast transformation in human lymphoid cultures stimulated by different agents.

Authors:  A Dimitriu; M Dy; N Thomson; C Bona
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

6.  Migration enhancement factor: a new lymphokine.

Authors:  R H Weisbart; R Bluestone; L S Goldberg; C M Pearson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

7.  Reversible interaction of human lymphocytes with the mitogen concanavalin A.

Authors:  A E Powell; M A Leon
Journal:  Exp Cell Res       Date:  1970-10       Impact factor: 3.905

8.  Studies on the inhibition of macrophage migration induced by soluble antigen-antibody complexes.

Authors:  P Kotkes; E Pick
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

9.  Migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity.

Authors:  S B Salvin; J S Youngner; W H Lederer
Journal:  Infect Immun       Date:  1973-01       Impact factor: 3.441

10.  Macrophage receptors for migration inhibitory factor (MIF), migration stimulatory factor (MSF), and agglutinating factor.

Authors:  R A Fox; D S Gregory; J D Feldman
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

View more
  6 in total

1.  Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens.

Authors:  A K Lee; M Eisinger
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

Review 2.  Cell-mediated immunity and its role in resistance to infection.

Authors:  E J Wing; J S Remington
Journal:  West J Med       Date:  1977-01

3.  Leukocyte migration inhibitory factor (LMIF) profile in primary and secondary immunodeficiency disease.

Authors:  A J Górski; B Dupont; J A Hansen; R O'Reilly; E Smithwick; R Górska; R A Good
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

4.  Rationale for combined use of fetal liver and thymus for immunological reconstitution in patients with variants of severe combined immunodeficiency.

Authors:  R Pahwa; S Pahwa; R A Good; G S Incefy; R J O'Reilly
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

5.  Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: T-lymphocyte-mediated immunosuppression.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

6.  Inhibition of leucocyte migration by stimulated mononuclear cell supernatants from patients with ischaemic heart disease.

Authors:  S K Das; L D Stein; P J Thebert; R T Reynolds; J T Cassidy
Journal:  Br Heart J       Date:  1983-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.